Search

Zentalis Pharmaceuticals Inc

Lezárt

3.75 -1.83

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

3.74

Maximum

3.96

Fő mutatók

By Trading Economics

Bevétel

-42M

-78M

Egy részvényre jutó nyereség

-0.59

Munkavállalók

106

EBITDA

-42M

-77M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+131.15% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 6.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

20M

351M

Előző nyitás

5.58

Előző zárás

3.75

Zentalis Pharmaceuticals Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 24. 23:56 UTC

Community Healthcare Trust Inc. shares are lower in after-market hours amid broader market caution related to geopolitical tensions and new U.S.-Iran sanctions.

2026. aug. 24. 23:56 UTC

Ares Capital Corp shares are trading roughly flat in after-hours. The stock remains above its 20-day moving average amid broader market caution.

2026. aug. 24. 23:56 UTC

Social Media

DICK'S Sporting Goods shares are higher in after-market trading as investors await earnings announcement tomorrow, despite earlier pulling back from a session high.

2026. aug. 24. 23:56 UTC

Dillard's Inc shares are lower in after-market hours amid cautious market sentiment influenced by geopolitical tensions and economic concerns.

2026. aug. 24. 23:56 UTC

Axon Enterprise Inc. shares advanced in after-market trading, following a higher close on Monday amid heightened market caution regarding U.S.-Iran relations and new sanctions.

2026. aug. 24. 23:56 UTC

Dycom Industries Inc shares are higher in after-market trading, reflecting a positive shift after five consecutive sessions of lower closes.

2026. aug. 24. 23:56 UTC

Vontier Corp shares traded roughly flat in after-market hours, remaining within a routine range since Monday's close.

2026. aug. 24. 23:56 UTC

Resmed Inc. shares are lower in after-market hours amid weak trading sentiment. No specific company news was identified to explain the decline.

2026. aug. 24. 23:56 UTC

Morgan Stanley shares are higher in after-market trading following Monday's close. The stock reached a session high earlier in the session.

2026. aug. 24. 23:56 UTC

Kanzhun Ltd shares increased in after-market trading, despite no specific news. Investor caution remains amid concerns over U.S.-Iran relations and economic implications.

2026. aug. 24. 23:56 UTC

Gogo Inc. shares are lower in after-market trading, continuing a decline since Monday amid broader market caution over geopolitical tensions and oil supply concerns.

2026. aug. 24. 23:56 UTC

Textron Inc shares are lower in after-market hours amid broader market caution linked to U.S.-Iran tensions and new sanctions affecting oil supply.

2026. aug. 24. 23:56 UTC

Dominion Energy shares are higher in after-market trading, reflecting a modest increase since Monday's close. The stock remains below its 20-day moving average.

2026. aug. 24. 23:56 UTC

Chipotle Mexican Grill Inc shares are lower in after-market hours amid broader market caution linked to geopolitical tensions and new sanctions affecting economic conditions.

2026. aug. 24. 23:56 UTC

Mid-America Apartment Communities shares are lower in after-market hours, reflecting notable volatility amid cautious broader market sentiment over geopolitical tensions.

2026. aug. 24. 23:56 UTC

Kulicke and Soffa Industries shares are higher in after-market hours, reflecting positive movement since Monday's close amid broader market caution.

2026. aug. 24. 23:56 UTC

Watsco Inc. shares are lower in after-market trading, continuing a trend of four consecutive daily declines and remaining below the 20-day moving average.

2026. aug. 24. 23:56 UTC

NRG Energy Inc shares are trading higher in after-market hours. Broader market dynamics may be influencing investor sentiment amid concerns over U.S.-Iran relations.

2026. aug. 24. 23:56 UTC

Markel Group Inc. shares declined in after-market trading amid broader market caution related to geopolitical tensions and new sanctions, now 2.90% below its 20-day moving average.

2026. aug. 24. 23:56 UTC

Match Group Inc shares are lower in after-market trading. Broader market caution persists amid concerns over U.S.-Iran relations and oil supply disruptions.

2026. aug. 24. 23:56 UTC

General Mills Inc shares are lower in after-market hours, reflecting volatility amid broader market caution over U.S.-Iran relations and potential oil supply disruptions.

2026. aug. 24. 23:56 UTC

Correlated Moves

The US 30Y Treasury Bond Index is trading lower amid market caution over U.S.-Iran tensions and new sanctions impacting oil supply concerns.

2026. aug. 24. 23:52 UTC

APA Corp. shares are trading higher in after-market hours, reflecting a routine move. The stock has seen notable gains over the past month.

2026. aug. 24. 23:51 UTC

Hyatt Hotels Corp shares are lower in after-market hours, following a notable dip earlier amid volatility in U.S. Treasury yields and inflation concerns.

2026. aug. 24. 23:51 UTC

HP Inc. shares are lower in after-market hours, reversing a recent trend of higher daily closes despite an earlier rebound from session lows.

2026. aug. 24. 23:51 UTC

Shares of Science Applications International Corp. are lower in after-market trading, declining from earlier session peaks amid no specific news or developments.

2026. aug. 24. 23:51 UTC

ArcBest Corp shares are lower in after-market hours, continuing weak trading conditions. The stock remains below its 20-day moving average and near recent lows.

2026. aug. 24. 23:51 UTC

PENN Entertainment Inc shares are higher in after-market trading, despite remaining near the lower end of their one-month range and below the 20-day moving average.

2026. aug. 24. 23:51 UTC

Correlated Moves
Social Media

SPDR Gold Shares are higher in after-market hours, continuing a recent upward trend amid mixed global equity indices and rising silver prices.

2026. aug. 24. 23:51 UTC

Deluxe Corp's shares are lower in after-market trading, reflecting weaker performance below its 20-day moving average and near the lower end of its one-month range.

Társak összehasonlítása

Árváltozás

Zentalis Pharmaceuticals Inc Előrejelzés

Célár

By TipRanks

131.15% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 8.83 USD  131.15%

Magas 11 USD

Alacsony 5 USD

6 Wall Street elemző 12 hónapos célárain alapulva a(z)Zentalis Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

6 ratings

5

Vétel

1

Tartás

0

Eladás

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat